For instance, a potential Parp1 inhibitor, Veliparib (ABT-888), with oral bioavailability and the ability to cross the blood-brain barrier, has proven to suppress tumor progress in BRCA1 deletion and the BRCA2 mutation breast cancer xenograft model [73]. The gene discussed is PARP1; the disease is neoplasm.